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ABSTRACT
This review article deals with the analysis and the detection of the morphological 
features associated with somatic mutations, mostly BRAFV600E mutation, on both 
cytological and histological samples of carcinomas. Few authors demonstrated that 
some architectural and specific cellular findings (i.e. polygonal eosinophilic cells 
defined as “plump cells” and sickle-shaped nuclei) are able to predict BRAF V600E 
mutation in both cytological and histological samples of papillary thyroid carcinoma 
(PTC) as well as in other carcinomas. In the current review article we evaluated 
the first comprehensive analysis of the morphological prediction of BRAFV600E and 
other somatic mutations in different malignant lesions with the description of 
the possible mechanisms beneath these morphologic features. The detection of 
predictive morphological features, mostly on FNAC, may add helpful information to 
the stratification of the malignant risk and personalized management of cancers. 
Additionally, the knowledge of the molecular mechanism of different oncogenic drivers 
can lead to the organ-specific triaging selection of cases and can provide significant 
insight for targeted therapies in different malignant lesions.
INTRODUCTION
The recent findings of specific morphological 
parameters associated with BRAFV600E neoplasms offer a 
promising and foreseeable insight into the morphological 
detection of somatic mutations supported also by the 
high specificity and positive predictive value of these 
parameters [1-6]. In this regard, this “morphological” 
evaluation seems to represent a valid and predictive 
support which may balance the difficulties in the use of 
DNA-based molecular analysis. Conversely, it is mostly 
performed with molecular platforms including different 
types of sequencing [3-4,7-11]. Despite their invaluable 
advantages, little reluctance might be ascribed to the fact 
that they are more inquiring, and less cost-effective for 
their worldwide diffusion in any laboratory [7-11]. 
Several studies, referring to different malignant 
neoplasms such as melanomas, hairy-cell leukemia 
(HCL), colon carcinoma (CC), ovarian low-grade serous 
carcinoma (LGSC), Langerhans cell histiocytosis and 
                  Review
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Erdheim-Chester disease (ECD) and glial neoplasms 
[12-21] have demonstrated the diagnostic and prognostic 
involvement of BRAFV600E mutation in the molecular 
mechanism of cancers. 
Additionaly, in papillary thyroid carcinoma (PTC) 
, BRAF V600E mutation was found to be associated with 
some distinctive architectural and cellular morphological 
features (specifically plumps cells defined by polygonal 
eosinophilic cytoplasms and and sickle-shaped nuclei) 
with significant diagnostic accuracy [1-4]. 
Accordingly, these promising morphological 
insights were underscored in a recent study pointing to the 
detection in BRAFV600E ovarian neoplastic lesions [5]. In 
this context, the authors identified a population of BRAF 
V600E ovarian cells, characterized by the same abundant 
eosinophilic cytoplasm (EC) among the “ovarian atypical 
proliferative serous tumours” [5]. Furthermore, owing 
to the histological and molecular features, the authors 
suggested that BRAFV600E mutation is highly likely to 
activate neoplastic initiation followed by a mechanism to 
restrain tumor progression and reach low-stage senescent 
disease as previously observed in vitro [5].
Peculiar morphological findings have been described 
in other BRAF-driven mutated cancers. In fact, hairy cell 
leukemia (HCL), characterized by specific morphological 
features (namely abundant eosinophilic cytoplasm and 
“hairy” membranous projections), demonstrate that 
BRAFV600E mutation is the disease-defining genetic event 
inasmuch as this mutation is present in virtually all the 
HCL cases but rarely in other B-cell lymphomas [16-17]. 
Similarly, foamy and eosinophilic cytoplasms have been 
appreciated in several Langerhans cell histiocytosis and 
Erdheim-Chester disease (ECD) harbouring BRAFV600E 
mutation [15].
Not surprisingly, some other neoplasms are likely to 
demonstrate a correlation between molecular alterations 
and distinctive morphological features. In fact, PDGFRA 
mutations in gastrointestinal stromal tumors (GISTs) 
have been found to correlate with several noteworthy 
morphological features (i.e. epithelioid morphology of 
tumor cells and tumor-infiltrating mast cells) allowing 
histological discrimination from GISTs with c-kit 
mutations. [19] Additionally, ALK translocations have 
been exclusively reported in lung carcinomas belonging 
to the acinar and solid predominant adenocarcinomas 
hystotypes [20]. 
In this review article we emphasize that, 
investigating the genetic underpinnings of the detection 
of morphological features link to some somatic mutations 
on both cytological and histological samples of different 
malignant entities may pave the way for obtaining an 
accurate knowledge of the molecular mechanism of 
different oncogenic drivers. Hence, this knowledge may 
lead to the organ-specific triaging selection of cases 
in order to provide important insight for future tailored 
targeted therapies in different malignant lesions
BRAFV600E AND THYROID
Numerous studies have found a strict association 
between thyroid carcinoma and activating somatic 
mutations in the BRAF oncogene demonstrating a high 
prevalence of these mutations mostly in the classical 
papillary thyroid carcinoma (PTC) and/or its more 
aggressive variant (including for instance tall cell variant-
TCV and sclerosing variant of PTC-SVPTC) [7-8, 21-30]. 
According to literature, the majority of BRAF mutations 
(more than 90%) involve the exon 15 with a final valine 
to glutamine substitution in the Braf protein (V600E) 
[21-26]. Nikiforov recognized that BRAFV600E,RAS, RET/
PTC and PAX8/PPARγ were associated with malignancy 
in almost 100% of thyroid lesions demonstrating the role 
of somatic mutations and/or rearrangements in everyday 
practice [31-35]. Given that, in thyroid oncology, 
BRAF V600E mutation is strongly associated with thyroid 
carcinoma mainly with the classical PTC hystotype..
Besides the diagnostic role of BRAFV600E mutation as 
a specific hallmark of thyroid tumorigenesis, this mutation 
has also provided significant insights into the prognostic 
unfavourable outcome of mutated carcinomas [24-27]. 
Despite contrasting evidence, BRAFV600E has been found 
in cases with higher tumor aggressiveness demonstrated 
by more frequent local or distant metastases, multifocality 
and infiltration of the peri-thyroid tissue. [24-27, 36-39]. 
The recognition of this subset of patients with a specific 
genotype and aggressive phenotype induced Finkelstein 
[4] and Virk [3] to analyze the correlation between 
BRAFV600E mutation and some specific architectural and 
cellular morphological parameters in the histological 
PTCs. Specifically this discovery included the evidence 
of foreseeable predictive features such as the presence 
of more infiltrative borders of the carcinomas, numerous 
psammoma bodies, well-developed features of PTC and 
peculiar polygonal cells with abundant and eosinophilic 
cytoplasms (defined as “plump cells”). In fact, Virk 
applied the term “plump cells” in order to define these 
large polygonal neoplastic cells, with nuclear features of 
PTCs but also with their height, less than twice the width, 
with squamous metaplasia and mostly with eosinophilic 
cytoplasms [3]. They demonstrated these peculiar cells in 
72% of their BRAFV600E PTCs but also in 28% of the wild 
type PTCs [3]. Their yields confirmed the data previously 
published by Finkelstein demonstrating plump in 65% of 
the BRAFV600E PTCs [4].
Taking into account these findings, we were 
tempted to search for the same morphological features 
in our series of thyroid lesions diagnosed as positive for 
malignancy (favouring PTC) on cytology and processed 
with liquid based cytology (LBC). [1-2]. For the reason 
that we were searching these parameters on cytological 
specimens, we were likely to address our study only to 
the cellular features mostly directed to recognize these 
large polygonal eosinophilic tumor cells characterized by 
Oncotarget3748www.impactjournals.com/oncotarget
nuclear features of PTC and homogeneous, moderate to 
abundant cytoplasms. The same morphological parameters 
were assessed on the corresponding histological samples. 
In contrast with the detection of “plump cells” in 72% of 
Virk’s BRAFV600E cases; we recognized them in 100% of 
the mutated cases even if with a different intensity in the 
eosinophilic cytoplasms which may be attributed to the 
use of LBC [1-2;Figure 1]. Moreover, 
the quantitative definition of these cells represents 
an additional critical parameter. Virk and Finkelstein 
appraised that even focal “plump cells” are correlated 
with BRAF V600E mutation and this evidence was also 
found in our  12.7% of the BRAF V600E mutated cases with 
focal “plump cells” [3-4]. Additionally we had 5 out of 
25 wild type cases with focal “plump cells” [1]. In our 
opinion, in the interpretation of focal “plump cells”, there 
may be a problematic semi-quantitative evaluation of the 
percentage score which might not be predictive of the 
BRAF V600E status. Importantly, for the first time to date, 
we reported the evidence of a particular and patognomonic 
nuclear shape in all the BRAF V600E cases. Specifically, 
these nuclei were smaller, in eccentric position and with a 
sickled shape which was absent in wild type BRAF cases 
[1-2; Figure 1]. The sickle-shaped nuclei, characterized by 
nuclear grooves and pseudo inclusions, had also irregular 
nuclear membranes. The same morphological parameters 
were recognized on the corresponding histological 
samples (Figure 2).
Figure 1: Details of the morphological features of plump cells and sickle shape nuclei in a cluster of “positive for 
malignancy” thyroid cells on liquid based cytology (LBC, 40X)
Figure 2: Specific histological details of polygonal cells with homogeneous eosinophilic cytoplasm (plump cells) in the 
bottom of the picture obtained from a Follicular variant of PTC (FVPC- H&E 60X)
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In this perspective, the morphological evidence 
of altered nuclei/cytoplasm ratio (favoring a moderate/
abundant cytoplasm in BRAFV600E PTCs) cannot refute 
the argument that mutated cancer cells had a different 
metabolism due to the effect of mutated oncogenes on the 
pathway [7,12;Figure 3]. 
However, all these papers, including ours, 
limited their analysis to acknowledge the correlation 
of these “plump cells” with BRAF V600E mutation in the 
PTCs without any description or study concerning the 
mechanisms beneath their nature [1-4].
Among authors, Hall suggested that these 
morphological findings are the consequence of the 
“Warburg effect” consistent in the ability of cancer 
cells of converting glucose to lactic acid [12; Figure 3]. 
According to their studies, Hall et al suggested that this 
effect may induce the activation of RAS-BRAF-MEK-ERK 
pathways which stimulate glycolysis also when there is 
presence of glucose [12-13, 40-41]. In this perspective, 
this up-regulation of glycolisis gene in BRAF mutated 
cells, may lead to an increased mitochondrial respiration 
justifying the abundant and eosinophilic cytoplasm of the 
Figure 3: Comparative analysis of normal and neoplastic cells and “Warburg effect” pioneering the ability of cancer 
cells of converting glucose to lactic acid
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cells [12-13, 42-43]. In this perspective, one explanation 
of this cytoplasm feature may be ascribed to the role 
of glycolysis through the accumulation of the lactate 
which was highlighted by the immunocytochemical 
analysis of the monocarboxylate (MCT) family. In fact, 
MCTs are involved in regulation of lactate and other 
monocarboxylates across cellular membranes.[44-50]. 
Inasmuch as glycolisis stimulates the accumulation of 
high amount of lactate inside cancers cells, MCTs regulate 
the maintenance of the intracellular PH of the neoplastic 
cells through the extrusion of lactate. According to 
literature, MCTs are transmembrane proteins including 
14 members even thoughonly the first 4 MCTs,(MCT1-4), 
are involved in the regulation of lactate and other MCTs 
across cellular membranes. The role of MCTs in thyroid 
BRAFV600E carcinomas has not been completely defined so 
that their use as potential therapeutic targets needs to be 
demonstrated with practical application [51]. In our recent 
experience, we found that plump PTC cells yielded high 
positive predictive value (92%) and specificity (87%) for 
MCT1 whilst high predictive values and sensitivity for 
MCT4 [52].). Their expression clearly depicts that the 
different metabolism of BRAF V600E cells (involving the 
up-regulation of gene associated with glycolysis) may 
be responsible for the abundant eosinophilic cytoplasm 
of the plump cells [13-14]. Together, a recent study by 
Lee prospected the evidence of BRAFV600E mitochondrial 
translocation involving both a metabolic remodeling and 
an anti-apoptotic effect through the caspases 3-9 [13]. 
In fact, it has been demonstrated that this 
localization confers apoptotic resistance and the 
characteristic metabolic phenotypes associated with 
suppressed oxidative phosphorylation due to the bind 
between BRAFV600E and mitochondrial interacting 
molecules, which have not already been, identified [34]
In this regard, a possible molecular hypothesis, 
which might justify the higher aggressiveness encountered 
in mutated PTC, seems to involve the BRAF V600E 
localization within the outer mitochondrial membrane. 
This evidence may imply a novel and potential therapeutic 
approach for the treatment of patients. 
Figure 4: Histological details of the morphological features of plump cells on serous borderline mutated ovarian case 
(H&E 60X)
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BRAFV600E MUTATION IN OVARIAN 
NEOPLASMS 
Among the broad range of human tumors found 
to harbor BRAF mutation, ovarian neoplasms, including 
atypicalproliferative serous tumors (APSTs) and low 
grade serous carcinomas (LGSCs), account for two thirds 
mutated cases in different series by literature [5-6, 51-61]. 
However, Zeppernick examined its association with the 
clinicopathological characteristics in ovarian neoplasms 
[5-6]. 
More specifically, Zeppernick described some 
specific morphological features in 71atypical proliferative 
serous tumors (APSTs) and 18low grade serous 
carcinomas (LGSCs) and therefore their association with 
KRAS and BRAF mutations. They demonstrated that all 
the BRAFV600E ASPTs were characterized by abundant 
eosinophilic cytoplasm (EC) whilst only 2 BRAFV600E 
LGSCs presented the same EC cells. Furthermore, the 
immunohistochemical studies revealed that these EC 
cells were characterized by low Ki-67 proliferation 
index, significant decrease in steroid hormone receptors 
and strong p16 expression [5]. Owing to the histological 
and molecular features, the authors suggested that 
BRAFV600E mutation is highly likely to activate 
neoplastic initiation followed by a mechanism able to 
restrain tumor progression and to increase low-stage 
senescent disease, as previously observed in vitro [6]. 
Despite the same morphological evidence of BRAFV600E 
mutation in both ovarian (Figure 4) and thyroid neoplasms, 
we hypothesize that BRAFV600E activating mutation may 
produce a different or/and opposite effect on different body 
sites controlled by a specific metabolism and/or hormonal 
status. Hence, despite the similarities of cellular features 
associated with BRAFV600E mutation, it also activates 
organ-specific molecular mechanisms enabling different 
prognostic prediction in these cancers [5-6].
Given that, the association between BRAFV600E 
mutation and ovarian morphology demonstrates 
the pathogenesis of these specific lesions with an 
“oncogene-induced senescence” phenotype as described 
by Zeppernick, which may block the progression of 
Figure 5: Details of the molecular mechanisms involving BRAF mutation in the different cell localizations
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the precursor (APSTs) to cancer (LGSCs). Eventually 
the identification of EC cells may help in planning a 
personalized management especially because the majority 
of APSTs do not progress to LGSCs.
BRAFV600E MUTATED MELANOMAS
As partially described in thyroid chapter, some 
of the mechanisms proposed as responsible for the 
morphological features in mutated PTCs had been 
borrowed from the literature concerning BRAFV600E 
melanomas [12, 62-73].  Haq in his papers assessed 
that BRAFV600E mutation is the most frequent genetic 
mutation in melanomas and the activation of the BRAF/
MAPK decreases the oxidative metabolism [66-67]. As 
Salama and Flaherty summarized, BRAF V600E has 
garnered a great deal of attention in these years especially 
as the most frequent oncogenetic mechanism in up to 
Figure 6: A. Histological details of the morphological features of cells on mutated intestinal adenocarcinoma case (H&E 60X); B. 
Histological details of the morphological features of cells on wild type intestinal adenocarcinoma case (H&E 60X).
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60% of the cutaneous melanomas [62]. Nonetheless, 
these authors did not underline any correlation with 
specific phenotype of mutated melanoma cells. However, 
despite this lack of evidence, some authors found a higher 
incidence of BRAFV600E in melanomas developed on 
body sites intermittently exposed to the sun than those 
arisen in areas with chronic exposure [63]. Furthermore, 
Kim showed an association between BRAFV600E 
mutation and different types (acral lentiginous melanoma) 
and spreading of melanoma (superficial or  nodular 
melanoma)[63]
On the other hand, Hall assessed that most cancer 
cells, including melanoma cells, display a strikingly 
different metabolism that is generated by intrinsic and 
extrinsic factors [12]. These authors proved the first 
evidence that BRAFV600E mutation stimulates the 
upregulation of gene involved in glycolysis in mutated 
melanoma cell lines [12]. Therefore, their results suggested 
that BRAF activation is associated with reduction of 
oxidative enzymes, mitochondrial number and alterations 
in the lactate (increasing amount). In contrast with the data 
from thyroid cancer cell, Hall did not find evidence of 
BRAF correlated suppression of oxidative phosphorylation 
in melanoma cells. This metabolic reprogramming 
triggered by BRAFV600E is linked with the suppression 
of melanocyte master regulator microphthalmia-associated 
transcription factor (MITF) and mitochondrial master 
regulator (PGC1α) representing the major regulator of 
mitochondrial biogenesis and function [67-71; Figure 5]. 
Taking into account the results published in BRAF 
mutated melanomas, though unproved on thyroid PTCs, 
BRAF inhibition also stimulates some gene programs such 
as oxidative phosphorylation, mitochondrial mechanisms, 
and the levels of PGC1α [67-71, 74]. Given that, the 
activation of the BRAF/MAPK pathway may suppress 
levels of MITF and PGC1α and decrease oxidative 
metabolism [14, 72]. Data reported from melanomas 
cells, demonstrated that oncogenic BRAF promotes 
melanoma metastasis and aggressiveness through the 
down-regulation of the cyclic GMP (cGMP)-specific 
phosphodiesterase PDE5A with interaction between 
RAS/RAF and cAMP pathway [14,72]. Arozarena had 
previously demonstrated that BRAF V600E increases 
the levels of BRN2 ( a transcriptor factor) in melanoma 
cells, which is responsible for invasiveness [64-65]. 
Additionally, it binds to the PDE5A promoter that is 
essential for the suppression of the PDE5A transcription 
by BRAF V600E. Despite the demonstration of these 
mechanisms in both in vivo and in vitro studies and cell 
lines, to date, they have not been correlated with peculiar 
morphological evidence on melanoma cells. 
BRAFV600E IN HEMATOLOGICAL 
NEOPLASMS 
As reported by Davies, BRAF oncogene was found 
mutated also in some specific hematological neoplasms 
including hairy cell leukemia but also Langerhans 
cell histiocytosis and Erdheim-Chester disease [75-
76]. In 2014, Machnicki discussed the role of BRAF in 
hematological entities even though it has not been clearly 
defined [77]. Although the oncogenic role of BRAFV600E 
has been reported in lymphoid and myeloid neoplasms, it 
seems to be mostly restricted to some specific subtypes. 
Conversely, the prevalence of BRAF V600E mutation 
in chronic and acute leukemias ranges between 0 and 
10% with only Gustafsson demonstrated that 20.7% of 
acute lymphoblastic leukemia (ALL) had BRAF V600E 
mutations [78]. Despite the fact that these BRAFV600E 
mutated cases are devoid of any morphological finding 
linked to the mutation, the detection itself, restricted to 
specific histotypes is a relevant feature as target for ERK 
pathway inhibitors. Hence, other attempts were made to 
determine whether BRAF mutations are present in multiple 
myeloma (MM) and plasma cell leukemia (PCL) [79-90]. 
Despite the low incidence of BRAF mutations in these 
entities, Andrulis found 2.8% BRAF V600E cases out of 
the 379 patients with plasma cell disorders [79].
On the other hand, the selectivity of BRAFV600E 
mutation is also clearly stated in hairy cell leukemia 
(HCL), an uncommon B-cell neoplasm in which 
BRAFV600E mutation represents an almost 100% 
disease-defining genetic abnormality [17, 86-91]. The 
pathognomonic features of typical hairy cells with 
abundant cytoplasm and circumferential distribution of 
fine hair-like projections on the cellular surface have been 
worldwide accepted [86-91]. Conversely, the fact that 
HCLs show the peculiar hairy cytoplasmic projections 
is likely to represent the morphological evidence of 
BRAFV600E mutation recalling plump cells especially 
for the abundant cytoplasms. On the other hand, these 
hairy cells are not reported in other BRAF negative B-cell 
leukemias [86-91]. As recently reviewed by McCarthy, 
the BRAFV600E-MEK-ERK pathway might be promoted 
by the production of ketones [40]. In this regard, Kang 
demonstrated that HMG-CoA lyase (HMGCL), involved 
in the ketogenesis pathway, activates the interaction 
between BRAFV600E and MEK leading to the subsequent 
phosphorylation of MEK1 as shown in hairy-cell leukemia 
and melanoma cells [41].
According to literature, this mutational status has 
its major correlation with the diagnosis and treatment 
of HCL, so as to help in the choice of targeted therapies 
(namely interferon-α [IF-α] and purine nucleoside analogs 
[PAs]) allowing a complete remission in the majority of 
patients. However, additional studies may be addressed to 
understand how ketones stimulate the interaction between 
BRAFV600E and MEK and their role in inducing the 
morphological findings.
Additionally BRAFV600E mutation was also 
detected in other two rare histiocytoses: Langerhans-
cell histiocytosis (LCH) and Erdheim-Chester disease 
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(ECD) characterized by a phenotype similar to CD1a+ 
S100+ Langerhans cells and foamy CD68+, CD1a- S100- 
histiocytes, respectively [15, 92-100]. Despite the 
controversy whether LCH and ECD are either flogistic 
entities or clonal neoplasms, the latter hypothesis is 
strongly supported by the detection of BRAF V600E 
mutation in up to half of the cases [92-98]. In the review 
article by Machnicki, the frequency of BRAF V600E 
ranged from 37.9% by Haroche to 68.8% by Satoh in LCH 
whilst it was at around 31.4% in ECD [77,100]. 
The high prevalence of BRAFV600E mutation 
restricted to these two histiocytoses is liable to encourage 
the management with vemurafenib or other ERK pathway 
inhibitors [100]. 
BRAFV600E IN CENTRAL NERVOUS 
SYSTEM NEOPLASMS
Several authors estimated that BRAFV600E 
represents a frequent mutation in ganglioglioma 
(GG) [101-105]. On the other hand, the prevalence of 
BRAFV600E mutation in other low-grade gliomas has 
not been clearly recognized. In their paper, MacConaill 
reported a single case of pilocytic astrocytoma with 
BRAFV600E mutation, whilst others pointed out that some 
diffuse astrocytomas (WHO grade II) harboured BRAF 
V600E mutation [101, 102, 105].
Somatic mutations and specifically BRAFV600E 
through the MAPK signaling have been reported in 60% 
of the pleomorphic xanthoastrocytoma (PXA) representing 
a rare low-grade glial neoplasm of the central nervous 
system mostly occurring in children and young adults 
[103]. Specifically largepleomorphic giant cells with some 
xanthomatous change and showing dense deposition of 
intercellular reticulin and eosinophilic granular bodies are 
the peculiar features that are found in  these tumors. It 
may be hypothesized that these cytoplasmic findings can 
be the effect of the altered cellular mechanisms activated 
by the somatic mutation. In this regard, the identification 
of BRAFV600E mutations, as commonly detected in 
PXAs, might help in discriminating them from classical 
glioblastoma multiforme and/or pilocytic astrocytoma 
[103,104]. The suggestion that BRAFV600E mutations is 
the hallmark of both PXA and GG is also demonstrated by 
the evidence that ganglioglioma (GG), shares significant 
clinicopathologic similarities with PXA, [102-104].
Moreover, Lee, in a series of 105brain tumors 
(including 51dysembryoplastic neuroepithelial tumors, 
14subependymal giant cell astrocytomas, 12glioblastoma 
with neuronal marker expression, and 28 pleomorphic 
xanthoastrocytomas) assessed 51% and 42.9% mutated 
cases in the dysembryoplastic neuroepithelial tumor and 
subependymal giant cell astrocytomas. This data may 
support and encourage the aid of specific tailored therapies 
[104] 
BRAFV600E IN GASTRO-INTESTINAL 
NEOPLASMS
The evidence of morphological features associated 
with BRAFV600E mutations have been found in colon 
neoplasms [18, 106-110]. Specifically, recent data suggest 
that BRAFV600E mutation is one of the most frequent 
molecular abnormalities identified in hyperplastic polyps 
and sessile serrated adenomas which are early precursor 
lesions in the pathway of carcinogenesis [106-107]. In 
contrast, traditional serrated adenomas may be associated 
with either BRAFV600E or KRAS mutations [108]. 
According to Rosty, BRAFV600E mutation was assessed 
in several sessile serrated adenoma/polyps with or without 
dysplasia and microvesicular hyperplastic polyps with a 
percentage ranging from 95 to 76%. Hence, in their paper 
they attributed the morphological features of globet cells 
tubulo-villous adenoma mainly to KRAS mutation [109]. 
The BRAF molecular correlation was also supported 
by the immunohistochemical positivity for VE1 suggesting 
a subclassification of polyps according to the mutation 
status. In this perspective, Mesteri proposed that the 
evaluation of serrated lesions with immunohistochemical 
or molecular BRAFV600E mutation may be the key to 
identify those lesions with higher potential to progression 
into BRAFV600E -mutated colorectal cancer [110; 
Figure 6A, 6B]. As assessed in the pictures 6a-6b the 
presence of BRAFV600E mutation induced the peculiar 
moderate-abundant cytoplasm, which were absent in wild 
type adenocarcinomas. These morphological features 
underline their unequivocal correlation with BRAFV600E 
mutation. Additionally, as reported by Rosenbaum et al, 
colon carcinomas harboring  BRAFV600E mutation are 
also characterized by the expression of programmed cell 
death 1( PD-1) and its ligand (PD-L1), microsatellite 
instability and a peculiar medullary morphology with 
frequent CD-8 positive tumor-infiltrating lymphocytes. 
Moreover, the PD-L1 expression in colorectal carcinomas 
is associated with a worse outcome as well as tumors with 
microsatellite instability.[111].
NOT ONLY BRAFBRAFV600E MUTATION 
AND MORPHOLOGICAL FINDINGS
Not only did some authors report a correlation 
between BRAFV600E mutation and morphological 
features but also other papers documented some specific 
morphological clues linked with other mutations [19, 
20, 112-115]. Although in 1998, the expression of c-kit 
protein associated with c-kit mutation has been considered 
a diagnostic hallmark of gastrointestinal stromal tumors 
(GISTs), a subset of them were c-kit wild type [114-115]. 
In fact, it has been well documented that a significant 
proportion of gastrointestinal stromal tumors (GISTs) 
harbour also activating mutations of platelet-derived 
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growth factor receptor a (PDGFRA). This latter mutation 
seems to be associated with peculiar morphological 
features allowing them to be discriminated from GISTs 
with c-kit mutations [19, 114-115]. Together, some 
authors, including Tajima, observed that GISTs with 
PDGFRA mutations are frequently characterized by 
epithelioid pattern, myxoid stroma, mast-cells infiltrating 
tumor, multi-nucleated neoplastic cells and some rhabdoid 
cells [19]. It stands to reason that, also among GISTs, 
the morphological finding may be a predictive factor of 
a sensitive mutation leading to personalized molecular-
targeted therapy [19,114-115].
In the same perspective, mutations in the V-Ki-
ras2 Kirsten rat sarcoma viral oncogne homologue 
(KRAS), epidermal growth factor receptor (EGFR), 
v-Raf murine sarcoma viral oncogene homologue B1 
(BRAF) and translocations of the anaplastic lymphoma 
kinase (ALK) gene locus have been found in several lung 
adenocarcinoma (ADC) with important implications 
for targeted therapies [20,112]. Warth highlighted that 
KRAS mutations were more frequently found in invasive 
mucinous ADCs whilst EGFR mutations were associated 
with lepidic growth and micropapillary ADCs [20]. On 
the other hand, ALK traslocations were recognized as 
oncogene drivers only in acinar and solid ADCs whilst 
BRAF mutation in micropapillary ADCs but not in 
papillary and lepidic ADCs [112]. This peculiar expression 
of mutations and/or translocations supports the association 
of morphology with predictive biomarkers impacting on 
the therapeutical management. 
The glucose metabolism was also essential for 
RAS-driven cancers as demonstrated in inducible 
mouse model for oncogenic KRASG12D pancreatic 
duct adenocarcinoma (PDACs) [113]. In her review 
article, White described the results obtained by Ying 
demonstrating that RAS promotes glucose uptake and 
glycolysis even though tissue specific findings remain to be 
addressed and studied [42]. This determination represents 
a question mark especially because it is important to prove 
if this metabolic pathway may be attributed uniquely to 
PDACs or to other RAS-driven cancers [113]. It has been 
said that RAS transformation induces autophagy, which 
is required for tumor growth and mitochondrial function, 
whilst knockdown of autophagy genes causes impaired 
tumor progression [42].
 Although RET proto-oncogene mutations are the 
most frequent mutation in medullary thyroid carcinoma 
(MTC) , the presence of RAS mutations in sporadic MTC 
has been documented by the induction of MTCs in rascal 
transgenic mice with v-Ha-ras under the control of a 
specific promoter [116]. It has been reported that 0–41.2% 
and 0–40.9% of the cases had HRAS and KRAS mutations 
respectively, whilst and between 0–1.8% with NRAS. 
However to the best of our knowledge, the different type 
of RET and RAS mutation did not match with specific 
morphological features [117].
CONCLUSIONS
The insights into the involvement of metabolic 
mechanisms of mutated-driven cancers seem to contribute 
to the morphological detection of several somatic 
mutations. Targeting these findings may shed light on 
new metabolic management and inhibitors as well as 
metabolic flaws. It  makes sense that the well-documented 
role of Warburg effect is a relevant characteristic of several 
tumors, which may justify the morphological effects of 
these mechanisms. Highlighting these morphological 
findings will represent a significant additional aid to prove 
a possible involvement of the metabolic processes. The 
knowledge of these metabolic finding of BRAF-driven 
cancers may raise additional researches and questions 
postulating that somatic mutations induce organ-specific 
molecular mechanisms enabling different prognostic 
prediction in different cancers.
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